Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
SODIUM CHLORIDE | IMPURITIES/Limit of Potassium/Instrumental conditions | Second Supplement to USP39–NF34 | 8821 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Mode: Change Atomic absorption spectrophotometry to: Atomic emission spectroscopy |
AMINOPHYLLINE INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 2737 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Theophylline Related Compound D RS: Change N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide. C6H10N4O 154.17 to: Theophyllidine; N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide hydrochloride… Read More |
<1058> ANALYTICAL INSTRUMENT QUALIFICATION | ANALYTICAL INSTRUMENT QUALIFICATION PROCESS/Qualification Phases | First Supplement to USP40–NF35 | 8083 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of paragraph 1 of Operational Qualification: Change OQ demonstrates fitness for the selected use, and should reflect the contents of the DQ document. to: OQ demonstrates fitness for the selected use, and should reflect URS. AND Line 2 of paragraph 3 of Operational… Read More |
BRINZOLAMIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 2788 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Brinzolamide Related Compound B RS: Change (R-4-Amino)-2,3-dihydro-2-(3-methoxypropyl)-4H-thieno[3,2,-e]-thiazine-6-sulfonamide-1,1-dioxide ethandioate 1:1. to: (R)-4-Amino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-… Read More |
ENTECAVIR | ASSAY/Procedure | USP39–NF34 | 3704 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 5 of Analysis: Change Result = (rU/rS) × (CS/CU) × (Mr1/Mr2) × 100 to: Result = (rU/rS… Read More |
CURCUMINOIDS | COMPOSITION/Content of Curcuminoids/Chromatographic system | USP39–NF34 | 6582 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Column: Change 4.6-mm × 20-cm; to: 4.6-mm × 25-cm; |
POWDERED TURMERIC EXTRACT | COMPOSITION/Content of Curcuminoids/Chromatographic system | USP39–NF34 | 6868 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Column: Change 4.6-mm × 20-cm; to: 4.6-mm × 25-cm; |
PROMETHAZINE HYDROCHLORIDE ORAL SOLUTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8787 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Promethazine Related Compound B RS: Change Isopromethazine; N,N-Dimethyl-2-(10H-phenothiazin-10-yl)propan-1-amine. C17H20N2S 282.42 to: Isopromethazine hydrochloride; N,N-Dimethyl-2-(10H-… Read More |
THEOPHYLLINE ORAL SOLUTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8846 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 3 of USP Theophylline Related Compound D RS: Change N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide. C6H10N4O 154.17 to: N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide hydrochloride monohydrate. C6… Read More |
GALANTAMINE EXTENDED-RELEASE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 3 | USP40–NF35 | 4367 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1of Buffer: Change To each L of 6.8-g/L potassium phosphate to: To each L of 6.8 g/L of monobasic potassium phosphate |
ATROPINE SULFATE | DEFINITION | USP39–NF34 | 2638 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2: Change (C17H23NO32 · H2SO4), to: [(C17H23NO3)2 · H2SO4], |
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM | IMPURITIES/Organic Impurities: Limit of Clotrimazole Related Compound A | USP39–NF34 | 3262 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | In the variable definition list in Analysis: Change CS = concentration of USP Clotrimazole Related Compound A RS in the Clotrimazole related compound A stock solution (mg/mL) to: CS = concentration of USP Clotrimazole… Read More |
TERAZOSIN TABLETS | IMPURITIES/Organic Impurities/Procedure | USP39–NF34 | 6045 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Sample solution: Change Transfer 15 mg of the powder from the crushed Tablets to: Transfer a suitable amount of powder, equivalent to 15 mg of terazosin hydrochloride, from the crushed Tablets |
TURMERIC | COMPOSITION/Content of Curcuminoids/Chromatographic system | USP39–NF34 | 6866 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Column: Change 4.6-mm × 20-cm; to: 4.6-mm × 25-cm; |
PROMETHAZINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8784 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Promethazine Related Compound B RS: Change Isopromethazine; N,N-Dimethyl-2-(10H-phenothiazin-10-yl)propan-1-amine. C17H20N2S 282.42 to: Isopromethazine hydrochloride; N,N-Dimethyl-2-(10H-… Read More |
TACROLIMUS CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 5 | Second Supplement to USP39–NF34 | 8834 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Medium: Change 0.5 g/L to: 0.05 g/L |
AMINOPHYLLINE ORAL SOLUTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 2739 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Theophylline Related Compound D RS: Change N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide. C6H10N4O 154.17 to: Theophyllidine; N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide hydrochloride… Read More |
ADENINE | CHEMICAL INFORMATION | USP39–NF34 | 2346 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2: Change 1H-Purin-6-amine; to: 9H-Purin-6-amine; |
BRINZOLAMIDE OPHTHALMIC SUSPENSION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 2789 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Brinzolamide Related Compound B RS: Change (R-4-Amino)-2,3-dihydro-2-(3-methoxypropyl)-4H-thieno[3,2,-e]-thiazine-6-sulfonamide-1,1-dioxide ethandioate 1:1. to: (R)-4-Amino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-… Read More |
HALCINONIDE | IMPURITIES/Organic Impurities/Chromatographic system | USP39–NF34 | 4175 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Column: Change 1.8-µm packing L1 to: 1.7-µm packing L1 |
CURCUMINOIDS CAPSULES | STRENGTH/Content of Curcuminoids/Chromatographic system | USP39–NF34 | 6583 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Column: Change 4.6-mm × 20-cm; to: 4.6-mm × 25-cm; |
GUAR GUM | ASSAY/Content of Galactomannan and Ratio of Constituting Mannose and Galactose | First Supplement to USP39–NF34 | 7964 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 4 of Analysis: Change Standard solution B to: Sample solution B |
DEXTROSE | IDENTIFICATION/C. Water Determination <921> | Second Supplement to USP39–NF34 | 8612 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1: Change Water Determination <921> to: Water Determination <921>, Method I |
<661.1> PLASTIC MATERIALS OF CONSTRUCTION | TEST METHODS | USP40–NF35 | 542 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Physicochemical Tests/Acidity or Alkalinity/BRP indicator solution: Change 1.0 mg/mL of bromophenol blue, to: 1.0 mg/mL of bromothymol blue, AND Line 3 of Plastic Additives/Polyethylene, Cyclic Olefins, and Polypropylene/Phenolic… Read More |
BETAXOLOL OPHTHALMIC SOLUTION | IMPURITIES/Organic Impurities | USP39–NF34 | 2749 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 14 of Analysis: Change Mr1 = molecular weight of betaxolol hydrochloride, 343.89 Mr2 = molecular weight of betaxolol, 307.43 to: Mr1 = molecular weight of betaxolol, 307.43 Mr2… Read More |
DIGOXIN ORAL SOLUTION | IDENTIFICATION/B. | USP39–NF34 | 3493 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Procedure: Change Proceed as directed for Procedure in the test for Related glycosides under Digoxin, except to omit the use of the Gitoxin standard solution. to: Apply 10 µL of the Test solution and 10 µL of the Standard solution… Read More |
CHONDROITIN SULFATE SODIUM | IMPURITIES | USP39–NF34 | 6566 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Residue on Ignition <281>: Change 20.0%–30.0% to: 20.0%–30.0% on the dried basis |
CIPROFLOXACIN | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8597 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Ciprofloxacin Ethylenediamine Analog RS: Change 7-(2-Aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. C15H16FN3O3 305.30 to: 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)… Read More |
POVIDONE | IMPURITIES/Formic Acid | Second Supplement to USP39–NF34 | 8778 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 3 of Sample solution: Change column of about 80 mm to: column of about 8 mm |
<661.2> PLASTIC PACKAGING SYSTEMS FOR PHARMACEUTICAL USE | TEST METHODS/Physicochemical Tests/Water Extraction/Acidity or alkalinity | USP39–NF34 | 506 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of Methyl red TS 2: Change NMT 0.1 mL of 0.02 N hydrochloric acid to: NMT 0.1 mL of 0.02 N sodium hydroxide |
DESMOPRESSIN ACETATE | IDENTIFICATION/A. Mass Spectral Analysis | USP39–NF34 | 3387 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 6 of Instrumental conditions: Delete Flow rate: 0.7 mL/min Injection volume: 10 µL/min |
SUCCINYLCHOLINE CHLORIDE INJECTION | IDENTIFICATION | USP39–NF34 | 5922 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1: Change It responds to Identification tests B and C under Succinylcholine Chloride. to: A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.… Read More |
MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities/Table 6 | First Supplement to USP39–NF34 | 8101 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Footnote c: Change (4R,4aS,5aR,12aS)-4-Dimethylamino-3,10,12,12a-tetrahydroxy-7-methylamino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide. to: (4S,4aS,5aR,12aS)-4-Dimethylamino-3,10,12,12a-tetrahydroxy-7-… Read More |
OMEGA-3-ACID ETHYL ESTERS CAPSULES | ASSAY/Content of EPAee, DHAee, and Total Omega-3-Acid Ethyl Esters | Second Supplement to USP39–NF34 | 8755 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 21 of Analysis: Change CU = nominal concentration of the total omega-3-acid ethyl esters in the Sample solution (g/mL) to: CU = Capsule fill content of the Sample solution (g/mL) |
DUTASTERIDE | IMPURITIES/Organic Impurities, Procedure 2/Table 4 | USP40–NF35 | 3924 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Footnote a: Change (5α,17β)-N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-17 carboxamide. to: (5α,17β)-N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrostane-17-carboxamide. |
CARBIDOPA | ASSAY/Procedure | USP39–NF34 | 2924 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 3: Change Mobile phase: Alcohol and 0.05 M monobasic sodium phosphate, adjusted with phosphoric acid to a pH of 2.7 (5:95) to: Buffer: 0.05 M monobasic sodium phosphate, adjusted with phosphoric acid to a pH of 2.7 Mobile phase: Alcohol and Buffer (5:… Read More |
DIGOXIN TABLETS | IDENTIFICATION/A. | USP39–NF34 | 3494 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Procedure: Change Proceed as directed for Procedure in the test for Related glycosides under Digoxin, except to omit the use of the Gitoxin standard solution. to: Apply 10 µL of the Test solution and 10 µL of the Standard solution… Read More |
<1207> STERILE PRODUCT PACKAGING−INTEGRITY EVALUATION | 5. PRODUCT–PACKAGE QUALITY REQUIREMENTS AND THE MAXIMUM ALLOWABLE LEAKAGE LIMIT/5.1 Sterility and Product Formulation Content must be Preserved; Gas Headspace Content Preservation is not Required | First Supplement to USP39–NF34 | 7764 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 3 of paragraph 5: Change ultra-cold storage (<80°) to: ultra-cold storage (≤−80°) |
CIPROFLOXACIN HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF35 | 8600 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Ciprofloxacin Ethylenediamine Analog RS: Change 7-(2-Aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. C15H16FN3O3 305.30 to: 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)… Read More |
ROPINIROLE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 1 | Second Supplement to USP39–NF34 | 8814 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of Buffer 1: Adjust with Solution A to a pH of 4.0. to: Adjust with Solution A to a pH of 4.0. Dilute with water to 1 L. |
<670> AUXILIARY PACKAGING COMPONENTS | DESICCANTS/Silica Gel/Inorganic Impurities | USP39–NF34 | 510 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Soluble ionizable salts: Change (as NaSO3): to: (as Na2SO4): |
DIGOXIN INJECTION | IDENTIFICATION/B. | USP39–NF34 | 3493 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Procedure: Change Proceed as directed for Procedure in the test for Related glycosides under Digoxin, except to omit the use of the Gitoxin standard solution. to: Apply 10 µL of the Test solution and 10 µL of the Standard solution… Read More |
POWDERED CHASTE TREE EXTRACT | CONTAMINANTS | USP39–NF34 | 6553 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Change Microbial Enumeration Tests <2021>: The total bacterial count does not exceed 104 cfu/g. The total combined molds and yeasts count does not exceed 1000 cfu/g. It meets the requirements of the tests for absence of Salmonella species and Escherichia coli… Read More |
NAPHAZOLINE HYDROCHLORIDE | IMPURITIES/Organic Impurities | First Supplement to USP39–NF34 | 8105 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 16 of Analysis: Change Calculate the percentage of any individual unspecified impurity to: Calculate the percentage of any other individual impurity AND Line 20 of Analysis: Change rU = peak response of any individual unspecified… Read More |
OMEGA-3-ACID ETHYL ESTERS CAPSULES | SPECIFIC TESTS/Concentration of Omega-3-Acid Ethyl Esters | Second Supplement to USP39–NF34 | 8755 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 21: Change CU = nominal concentration of the total omega-3-acid ethyl esters in the Sample solution (g/mL) to: CU = Capsule fill content of the Sample solution (g/mL) |
CYCLOBENZAPRINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 3333 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Cyclobenzaprine Related Compound B RS: Change 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine. C19H19N 261.36 to: 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine… Read More |
RIBOFLAVIN 5′-PHOSPHATE SODIUM | ASSAY/Procedure | USP39–NF34 | 5698 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of Instrumental conditions: Change Nephelometry, Turbidimetry, and Visual Comparison <855> to: Fluorescence Spectroscopy <853> |
NORFLOXACIN | SPECIFIC TESTS/Loss on Drying <731> | USP39–NF34 | 5101 | 30-Sep-2016 | 1-Oct-2016 | USP41–NF36 | First Supplement to USP40–NF35 | Line 1 of Analysis: Change Dry at 100° to constant weight. to: Dry under vacuum at a pressure not exceeding 5 mm of mercury at 100° to constant weight. |
PROPOFOL INJECTABLE EMULSION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 5575 | 30-Sep-2016 | 1-Oct-2016 | USP41–NF36 | First Supplement to USP40–NF35 | Line 2 of USP Propofol Related Compound B RS: Change 2,6-Diisopropylbenzoquinone. to: 2,6-Diisopropyl-1,4-benzoquinone. |
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS | APPENDICES/Appendix 3: Types of Biological Safety Cabinets/Class II | First Supplement to USP39–NF34 | 7721 | 30-Sep-2016 | 1-Oct-2016 | USP41–NF36 | First Supplement to USP40–NF35 | Line 5 of Type A1 (formerly, Type A): Change radionucleotides to: radionuclides AND Line 5 of Type A2 (formerly, Type B3): Change radionucleotides to: radionuclides AND Line 5 of Type B1: Change radionucleotides to: radionuclides … Read More |